Granisetron
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Granisetron
- Granisetron: From Chemotherapy-Related Nausea and Vomiting to Manic Bipolar Affective Disorder
Granisetron: From Chemotherapy-Related Nausea and Vomiting to Manic Bipolar Affective Disorder
One-Sentence Summary
Granisetron is a selective 5-HT3 receptor antagonist. It is marketed in Singapore as an injectable and oral product, but the data compiled for this report contain no approved indication text. The TxGNN model predicts it may be effective for manic bipolar affective disorder, but no clinical trials and no publications currently support this prediction. It rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the Singapore licence records |
| Predicted New Indication | Manic bipolar affective disorder |
| TxGNN Prediction Score | 99.62% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 7 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Granisetron is a selective 5-HT3 receptor antagonist. Detailed mechanism of action data are not available in the data compiled for this report, and the licence records give no approved indication text. Granisetron's established use, as a 5-HT3 antagonist anti-emetic, is general knowledge and is not confirmed by the compiled data.
The proposed link to mood disorders is speculative. 5-HT3 modulation has been hypothesised to influence dopaminergic and serotonergic signalling relevant to mood regulation. The high TxGNN score (0.996) is a model prediction only. It does not show clinical benefit.
Other lower-ranked predictions include Tourette syndrome, trichotillomania, angioedema, allergic urticaria, cold urticaria, bronchitis, conjunctivitis, acute contagious conjunctivitis and nephrogenic syndrome of inappropriate antidiuresis. Some have loose class-level rationale, for example the serotonergic and dopaminergic involvement in Tourette syndrome and trichotillomania. Others, such as nephrogenic syndrome of inappropriate antidiuresis and infectious conjunctivitis, have no plausible mechanistic link and are likely graph-based artefacts.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16589P | Granodex Solution for Injection 1 mg/ml | Injection, solution | Not specified |
| SIN07800P | Kytril Tablet 1 mg | Tablet, film coated | Not specified |
| SIN15174P | Emenat Tablets 1 mg | Tablet | Not specified |
| SIN14612P | Granisetron-AFT Solution for Injection 1 mg/ml | Injection, solution | Not specified |
| SIN07089P | Kytril for Infusion 3 mg/3 ml | Injection | Not specified |
Seven valid single-ingredient licences exist in total. Both injectable and oral forms are available.
Safety Considerations
- Knowledge-graph contraindication signals (from drug-disease network edges, not label text): long QT syndrome, familial long QT syndrome, potassium deficiency disease, sudden cardiac arrest and heart conduction disease. These point to a QT-prolongation concern.
- Drug Interactions: 100 interactions were identified. Examples of Major interactions include fentanyl, dextromethorphan, tramadol, alfentanil, almotriptan, sumatriptan, amiodarone, amisulpride, amitriptyline and anagrelide. These involve serotonergic and QT-prolonging combinations. Examples of Moderate interactions include abametapir, abiraterone, dihydrocodeine, codeine, famotidine, formoterol, adenosine, salbutamol, alfuzosin and propofol.
Please refer to the package insert for label warnings and contraindications, as these were not available.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has Evidence Level L5, with no clinical trials or literature. The mechanistic rationale is speculative. Safety signals around QT prolongation and serotonergic interactions matter in a psychiatric population, where co-medications are common.
To proceed, the following is needed:
- Package insert warnings and contraindications from HSA, which are currently missing and block safety screening
- Detailed mechanism of action data from DrugBank
- A literature and trial search for granisetron or 5-HT3 antagonists in bipolar mania
- Preclinical or mechanistic evidence supporting a role in mood regulation
- A QT and drug-interaction risk assessment for the target population
- Route and dosage compatibility assessment, which is currently pending
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.